Angiotensin II Type 1 Receptor Antagonist Enhances Cis-dichlorodiammineplatinum-Induced Cytotoxicity in Mouse Xenograft Model of Bladder Cancer

Urology

Volumn 73, Issue 3, 2009, Pages 655-660

  Kosugi, Michio ^a   Miyajima, Akira ^a   Kikuchi, Eiji ^a   Kosaka, Takeo ^a   Horiguchi, Yutaka ^b   Murai, Masaru ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; CISPLATIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TETRAZOLES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 60549083067     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.10.031     Document Type: Article

References (22)

1. Keane T.E., Gingrich J.R., Ronsner G., et al. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res 54 (1994) 475-481
2. Fujimoto Y., Sasaki T., Tsuchida A., et al. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495 (2001) 197-200
3. Egami K., Murohara T., Shimada T., et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112 (2003) 67-75
4. Miyajima A., Kosaka T., Asano T., et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62 (2002) 4176-4179
5. Kosugi M., Miyajima A., Kikuchi E., et al. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 12 (2006) 2888-2893
6. Kosaka T., Miyajima A., Takayama E., et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67 (2007) 41-49
7. Koh W.P., Yuan J.M., Van Den Berg D., et al. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26 (2005) 459-464
8. Juillerat-Jeanneret L., Celerier J., Chapuis Bernasconi C., et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 90 (2004) 1059-1068
9. Kosugi M., Miyajima A., Kikuchi E., et al. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Hum Cell 20 (2007) 1-9
10. Tachibana M., Miyakawa A., Nakashima J., et al. Constitutive production of multiple cytokines and a human chorionic gonadotropin beta-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiation. Br J Cancer 76 (1997) 163-174
11. Araki H., Fukushima M., Kamiyama Y., et al. Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in Vivo. Cancer Lett 160 (2000) 185-191
12. Kumar R., Yoneda J., Bucana C.D., et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 12 (1998) 749-757
13. Crew J.P., O'Brien T., Bradburn M., et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57 (1997) 5281-5285
14. Crew J.P. Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer. Eur Urol 35 (1999) 2-8
15. Eggert A., Ikegaki N., Kwiatkowski J., et al. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6 (2000) 1900-1908
16. Manenti L., Riccardi E., Marchini S., et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 4 (2005) 715-725
17. Miyahara Y., Yoshida S., Motoyama S., et al. Effect of cis-diammine dichloroplatinum on vascular endothelial growth factor expression in uterine cervical carcinoma. Eur J Gynaecol Oncol 25 (2004) 33-39
18. Wang X.J., Dong Z., Zhong X.H., et al. Transforming growth factor-beta1 enhanced vascular endothelial growth factor synthesis in mesenchymal stem cells. Biochem Biophys Res Commun 365 (2008) 548-554
19. Cohn R.D., van Erp C., Habashi J.P., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13 (2007) 204-210
20. Rivera E., Arrieta O., Guevara P., et al. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 85 (2001) 1396-1399
21. Rowinsky E.K. Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr 15 (1993) 25-37
22. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 (2007) 3942-3950